X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

U.S. Metastatic Prostate Cancer Diagnoses Increase After Reduction in PSA Screening

A reduction in prostate-specific antigen (PSA) screening in men aged 40 years and older was associated with an increase in metastatic prostate cancer diagnoses in the United States, according to results of a study presented at the 2021 ASCO Genitourinary Cancers Symposium.

Between 2008 and 2016, across all states, the mean percentage of men undergoing PSA screening decreased from 61.8% to 50.5%, while the mean incidence of metastatic prostate cancer at diagnosis increased from 6.4 to 9.0 per 100,000 (adjusted P<0.001 for both) (abstract 228).

Read the full article here. 

source: Clinical Oncology